Work

Effects of rifampin on the pharmacokinetics of copanlisib, a novel pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in cancer patients.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.e14559

Authors: Anna Spreafico, Michael B. Sawyer, Lillian L. Siu, Funan Huang, Susanne Reschke, Chenghua Xia, Zhaoping Yan, Isabelle Genvresse, Galia Cisternas, Andrea Kelly, Fatima Khan, Stefanie Reif, Camille Granvil

Institutions: Princess Margaret Cancer Centre, Cross Cancer Institute, Bayer (United States), Bayer (Germany), Bayer (Canada)

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891977480

Cites:

Cited by: 1

Related to: 10